Fulcrum Therapeutics(US:FULC) Globenewswire·2026-02-24 12:01Core Insights - Fulcrum Therapeutics announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD), showing a mean absolute HbF increase of 12.2% from a baseline of 7.1% to 19.3% at Week 12, along with improvements in hemolysis and anemia markers, and trends in vaso-occlusive crisis reduction [1][5][10] - The company plans to initiate a potential registration-enabling trial in the second half of 2026, following discussions with the FDA regarding the next study design [1][2][5] - As of December 31, 2025, Fulcrum had $352.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2029 [1][8][15] Recent Business Highlights - The 20 mg cohort of the PIONEER trial included 12 participants and demonstrated significant HbF induction and safety, with no treatment-related serious adverse events reported [5][10] - Fulcrum completed a public offering in December 2025, raising $164.2 million in net proceeds, which bolstered its financial position for advancing pociredir and other corporate purposes [5][7] - The company has decided not to advance its program for bone marrow failure syndromes into clinical development, focusing resources on pociredir and its benign hematology pipeline [5][10] Financial Results - Research and development expenses for Q4 2025 were $15.4 million, up from $11.7 million in Q4 2024, primarily due to costs associated with the PIONEER trial [6][7] - General and administrative expenses for Q4 2025 were $7.3 million, a slight decrease from $7.7 million in Q4 2024, attributed to lower professional services costs [7] - The net loss for Q4 2025 was $20.3 million, compared to a net loss of $16.6 million in Q4 2024, while the annual net loss for 2025 was $74.9 million, significantly higher than the $9.7 million loss in 2024 [7][16]